Bio-Rad Laboratories, Inc. logo
Bio-Rad Laboratories, Inc. (BIO)
Compare

Bio-Rad Laboratories, Inc. (BIO) Debt to Equity Ratio: 0.21

Is Bio-Rad Laboratories, Inc.’s debt to equity ratio high or low?

Bio-Rad Laboratories, Inc.'s debt to equity ratio of 0.21 is 66% above its 5-year average of 0.13, near the high end of its 5-year range (0.02–0.21).

The debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO) is 0.21 as of Tuesday, June 9, 2026. It is equal to its 12-month average by 0.00% (0.21).

BIO Debt to Equity Ratio Chart

BIO Debt to Equity Ratio
0.21+0.00% 1Y
Zoom

BIO Average Debt to Equity Ratio Chart

BIO Current vs Average Debt to Equity Ratio Chart

BIO Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.21

DEBT TO EQUITY RATIO AVG TTM

0.21

DEBT TO EQUITY RATIO AVG 3Y

0.18

DEBT TO EQUITY RATIO AVG 5Y

0.13

DEBT TO EQUITY RATIO AVG 10Y

0.13

DEBT TO EQUITY RATIO AVG 15Y

0.20

DEBT TO EQUITY RATIO AVG 20Y

0.28

CURRENT VS TTM AVG

+0.00%

CURRENT VS 3Y AVG

+16.67%

CURRENT VS 5Y AVG

+65.79%

CURRENT VS 10Y AVG

+57.14%

CURRENT VS 15Y AVG

+2.44%

CURRENT VS 20Y AVG

-25.88%

BIO Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Bio-Rad Laboratories, Inc. (BIO)0.210.210.180.13
Charles River Laboratories International, Inc. (CRL)$9.14B0.970.880.910.99
Hims & Hers Health, Inc. (HIMS)$6.46B2.341.180.600.40
Align Technology, Inc. (ALGN)$12.76B0.030.030.030.03
Hologic, Inc. (HOLX)$16.97B0.520.520.550.69
Moderna, Inc. (MRNA)$18.94B0.220.150.110.10
BioNTech SE (BNTX)$21.87B0.010.010.010.04
Mettler-Toledo International Inc. (MTD)$23.50B-99.1448.2326.0617.96
Waters Corporation (WAT)$24.19B0.580.761.732.93
Veeva Systems Inc. (VEEV)$27.37B0.010.010.010.02

Financial Health

Debt/Equity

0.21

Current Ratio

5.62

Bio-Rad Laboratories, Inc. Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bio-Rad Laboratories, Inc. Debt to Equity Ratio FAQ

What is the debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The debt to equity ratio for BIO stock is 0.21.
Is Bio-Rad Laboratories, Inc.'s debt to equity ratio high or low?
Bio-Rad Laboratories, Inc.'s debt to equity ratio of 0.21 is 66% above its 5-year average of 0.13, near the high end of its 5-year range (0.02–0.21).
What is the TTM average debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The TTM average debt to equity ratio for BIO stock is 0.21.
What is the 3Y average debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 3Y average debt to equity ratio for BIO stock is 0.18.
What is the 5Y average debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 5Y average debt to equity ratio for BIO stock is 0.13.
What is the 10Y average debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 10Y average debt to equity ratio for BIO stock is 0.13.
What is the 15Y average debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 15Y average debt to equity ratio for BIO stock is 0.20.
What is the 20Y average debt to equity ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 20Y average debt to equity ratio for BIO stock is 0.28.

Bio-Rad Laboratories, Inc. Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2025-12-310.21
2024-12-310.21
2023-12-310.16
2022-12-310.14
2021-12-310.02
2020-12-310.02
2019-12-310.11
2018-12-310.11
2017-12-310.15
2016-12-310.17
2015-12-310.17
2014-12-310.20
2013-12-310.20
2012-12-310.36
2011-12-310.42
2010-12-310.63
2009-12-310.59
2008-12-310.44
2007-12-310.47
2006-12-310.52
2005-12-310.65
2004-12-310.73
2003-12-310.48
2002-12-310.30
2001-12-310.70
2000-12-310.91
1999-12-311.19
1998-12-310.24
1997-12-310.25
1996-12-310.07

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Hercules, CA
7,700 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Norman D. Schwartz